21 February 2017
EMA/126719/2017
Inspections Human Medicines Pharmacovigilance Division
Committees and Inspections Department

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

mRNA sequence encoding the wild type human OX40L protein.

Brief description of the finished product

Solution of mRNA/lipid nanoparticle complexes for intra-tumoral injection.

Proposed indication

Treatment of solid tumours.

EMA / CAT conclusion

The procedure was finalised on 27 January 2017 for the following recommendation.

On the basis that the product:

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

- contains an active substance that consist of a recombinant nucleic acid molecule of biologic origin, namely the coding sequence of the human OX40L;
- is intended to be administered to human beings with a view to adding a genetic sequence;
- its therapeutic effect relates directly to the product of genetic expression of this sequence,

the EMA/CAT considers that the Product falls within the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.